[go: up one dir, main page]

WO2011060945A3 - Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires - Google Patents

Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires Download PDF

Info

Publication number
WO2011060945A3
WO2011060945A3 PCT/EP2010/007025 EP2010007025W WO2011060945A3 WO 2011060945 A3 WO2011060945 A3 WO 2011060945A3 EP 2010007025 W EP2010007025 W EP 2010007025W WO 2011060945 A3 WO2011060945 A3 WO 2011060945A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
fatty acid
polyunsaturated fatty
cardiovascular diseases
active pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/007025
Other languages
English (en)
Other versions
WO2011060945A2 (fr
Inventor
Antonio PARENTE DUEÑA
Paolo Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GP Pharm SA
CARMINATI GIUSEPPE PAOLO
SINGROSSI MARIA GABRIELLA
Defiante Farmaceutica SA
Original Assignee
GP Pharm SA
CARMINATI GIUSEPPE PAOLO
SINGROSSI MARIA GABRIELLA
Defiante Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112012011902A priority Critical patent/BR112012011902A2/pt
Application filed by GP Pharm SA, CARMINATI GIUSEPPE PAOLO, SINGROSSI MARIA GABRIELLA, Defiante Farmaceutica SA filed Critical GP Pharm SA
Priority to AU2010321248A priority patent/AU2010321248A1/en
Priority to CA2781434A priority patent/CA2781434A1/fr
Priority to CN201080052613XA priority patent/CN102711735A/zh
Priority to RU2012122886/15A priority patent/RU2012122886A/ru
Priority to EP10781842A priority patent/EP2501365A2/fr
Priority to MX2012005744A priority patent/MX2012005744A/es
Priority to JP2012539231A priority patent/JP2013511480A/ja
Publication of WO2011060945A2 publication Critical patent/WO2011060945A2/fr
Publication of WO2011060945A3 publication Critical patent/WO2011060945A3/fr
Priority to IL219874A priority patent/IL219874A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique se présentant sous la forme d'une capsule qui contient des esters d'alkyle d'acides gras polyinsaturés (PUFA) et des principes actifs pour le traitement et/ou la prévention de maladies cardiovasculaires.
PCT/EP2010/007025 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires Ceased WO2011060945A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2012539231A JP2013511480A (ja) 2009-11-20 2010-11-19 心血管疾患の治療のための原薬及び多価不飽和脂肪酸エステルのカプセル
AU2010321248A AU2010321248A1 (en) 2009-11-20 2010-11-19 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
CA2781434A CA2781434A1 (fr) 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsatures pour le traitement de maladies cardiovasculaires
CN201080052613XA CN102711735A (zh) 2009-11-20 2010-11-19 治疗心血管疾病的、活性药物成分与多不饱和脂肪酸酯的胶囊
RU2012122886/15A RU2012122886A (ru) 2009-11-20 2010-11-19 Капсулы активных фармацевтических ингредиентов и сложных эфиров полиненасыщенной жирной кислоты для лечения сердечно-сосудистых заболеваний
BR112012011902A BR112012011902A2 (pt) 2009-11-20 2010-11-19 cápsula farmacêutica
MX2012005744A MX2012005744A (es) 2009-11-20 2010-11-19 Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
EP10781842A EP2501365A2 (fr) 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires
IL219874A IL219874A0 (en) 2009-11-20 2012-05-17 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931024 2009-11-20
ES200931024A ES2364011B1 (es) 2009-11-20 2009-11-20 Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.

Publications (2)

Publication Number Publication Date
WO2011060945A2 WO2011060945A2 (fr) 2011-05-26
WO2011060945A3 true WO2011060945A3 (fr) 2012-01-19

Family

ID=43498490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/007025 Ceased WO2011060945A2 (fr) 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires

Country Status (14)

Country Link
EP (1) EP2501365A2 (fr)
JP (1) JP2013511480A (fr)
KR (1) KR20120117986A (fr)
CN (1) CN102711735A (fr)
AR (1) AR079428A1 (fr)
AU (1) AU2010321248A1 (fr)
BR (1) BR112012011902A2 (fr)
CA (1) CA2781434A1 (fr)
ES (1) ES2364011B1 (fr)
IL (1) IL219874A0 (fr)
MX (1) MX2012005744A (fr)
RU (1) RU2012122886A (fr)
TW (1) TW201141469A (fr)
WO (1) WO2011060945A2 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
SG11201407303SA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement des maladies de coagulation du sang
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles inflammatoires
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur sévère
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168014A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la polyneuropathie amyloïde familiale
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
EP2852571A4 (fr) 2012-05-23 2015-11-25 Cellix Bio Private Ltd Compositions et méthodes pour le traitement de la mucosite
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
KR101414873B1 (ko) * 2012-06-28 2014-07-03 보령제약 주식회사 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
KR101391551B1 (ko) * 2012-07-10 2014-05-02 보령제약 주식회사 심부전증 예방, 완화 및 치료용 약학 조성물 및 이를 포함하는 복합제제
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (fr) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions et methodes de traitement d'une inflammation et de troubles lipidiques
WO2014041445A2 (fr) * 2012-09-13 2014-03-20 Mahesh Kandula Compositions et procédés pour le traitement de l'hypertension et la gestion de la néphropathie diabétique
CN102895205A (zh) * 2012-11-09 2013-01-30 重庆市力扬医药开发有限公司 一种快速溶出的阿齐沙坦药物制剂
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
FR3002735B1 (fr) * 2013-03-04 2015-07-03 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
EP2974719B1 (fr) 2013-03-14 2019-08-28 Boryung Pharmaceutical Co., Ltd. Médicament combiné pharmaceutique
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
WO2016110865A1 (fr) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
RU2558855C1 (ru) * 2014-04-15 2015-08-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ получения микрокапсул лозартана калия в альгинате натрия
RU2577685C1 (ru) * 2014-09-19 2016-03-20 Александр Александрович Кролевец Способ получения нанокапсул лозартана калия в альгинате натрия
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
RU2605848C2 (ru) * 2014-10-10 2016-12-27 Александр Александрович Кролевец Способ получения нанокапсул лекарственных препаратов группы цефалоспоринов в интерфероне
CA2965449C (fr) 2014-10-27 2020-11-10 Cellix Bio Private Limited Sels ternaires d'ester monomethylique d'acide fumarique associes a la piperazine ou a l'ethylenediamine pour le traitement de la sclerose en plaques
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
RU2596476C1 (ru) * 2015-04-27 2016-09-10 Александр Александрович Кролевец Способ получения нанокапсул лекарственных растений, обладающих спазмолитическим действием
JP6298435B2 (ja) * 2015-10-28 2018-03-20 大原薬品工業株式会社 アンジオテンシンｉｉ受容体拮抗薬を含有する口腔内崩壊錠
CN106074542A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐软胶囊的制备方法
KR101914051B1 (ko) * 2018-07-13 2018-12-28 (주)바이오제닉스 숯이 함유된 이중 캡슐 및 이의 제조방법
CN114617264A (zh) * 2020-12-14 2022-06-14 深圳市前海小藻科技有限公司 具有高含量epa的植物胶囊制剂
JPWO2022145443A1 (fr) * 2020-12-28 2022-07-07

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1352648A1 (fr) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Compositions pharmaceutiques, comprenant de l' acide acétilsalicilique et de l'huile omega-3
EP1803440A1 (fr) * 2004-10-19 2007-07-04 GP Pharm S.A. Formulation pharmaceutique comprenant des microcapsules de statines en suspension dans des esters alkyliques d'acides gras polyinsatures (pufa)
WO2009087938A1 (fr) * 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited Préparation de capsules
US20090215852A1 (en) * 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (fr) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
TW284688B (fr) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
HUP0102260A3 (en) 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
HU226950B1 (en) 1999-11-03 2010-03-29 Richter Gedeon Nyrt The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it
CA2357982A1 (fr) 2001-09-28 2003-03-28 Bernard Charles Sherman Compositions solides contenant du ramipril
AU2003201071A1 (en) 2002-01-15 2003-07-30 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
AU2004206109A1 (en) 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
EP1653929A1 (fr) 2003-01-22 2006-05-10 Sandoz AG Composition pharmaceutique solide comprenant du ramipril
EP1694308A1 (fr) 2003-10-30 2006-08-30 Lupin Ltd. Formulations stables d'inhibiteurs d'ace, et methodes de preparation desdites formulations
WO2005070398A2 (fr) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
WO2005079751A2 (fr) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales de candesartan cilexetil
WO2005084648A1 (fr) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques comprenant du candesartan cilexetil
US20080311207A1 (en) 2004-09-08 2008-12-18 Manoj Varshney Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
RU2007120817A (ru) 2004-11-05 2008-12-10 Кинг Фармасьютикалз Рисерч Энд Дивелопмент Стабилизированные покрытие по отдельности частицы рамиприла, композиции и способы
WO2006076097A2 (fr) 2004-12-07 2006-07-20 Nektar Therapeutics Preparation non cristalline stable contenant du losartan
EP1674080A1 (fr) 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan
CA2596035A1 (fr) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Excipients non aqueux non ioniques pour administration topique et par voie orale d'agents actifs lies a un support
GR1006875B (el) 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
JP5628480B2 (ja) * 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー 医薬成分を含有するコーティングカプセル
US20070281000A1 (en) 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
WO2008001184A2 (fr) 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Composition solide
US20100035955A1 (en) 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
WO2008012371A1 (fr) 2006-07-28 2008-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de formes amorphes et cristallines de candésartan cilexétil par chromatographie sur colonne
US20080152717A1 (en) 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
EP1952806A1 (fr) 2007-02-01 2008-08-06 Helm AG Procédé de préparation des produits d'absorption de candesartan
EP1997479A1 (fr) 2007-05-31 2008-12-03 Helm AG Formulations stabilisées contentant du candesartan cilexetil amorphe pour l'administration orale

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1352648A1 (fr) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Compositions pharmaceutiques, comprenant de l' acide acétilsalicilique et de l'huile omega-3
EP1803440A1 (fr) * 2004-10-19 2007-07-04 GP Pharm S.A. Formulation pharmaceutique comprenant des microcapsules de statines en suspension dans des esters alkyliques d'acides gras polyinsatures (pufa)
US20090215852A1 (en) * 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia
WO2009087938A1 (fr) * 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited Préparation de capsules
EP2229939A1 (fr) * 2008-01-10 2010-09-22 Takeda Pharmaceutical Company Limited Préparation de capsules

Also Published As

Publication number Publication date
IL219874A0 (en) 2012-07-31
AR079428A1 (es) 2012-01-25
BR112012011902A2 (pt) 2017-10-10
MX2012005744A (es) 2012-12-05
CN102711735A (zh) 2012-10-03
RU2012122886A (ru) 2013-12-27
AU2010321248A1 (en) 2012-06-07
JP2013511480A (ja) 2013-04-04
ES2364011A1 (es) 2011-08-23
CA2781434A1 (fr) 2011-05-26
KR20120117986A (ko) 2012-10-25
WO2011060945A2 (fr) 2011-05-26
TW201141469A (en) 2011-12-01
ES2364011B1 (es) 2013-01-24
EP2501365A2 (fr) 2012-09-26

Similar Documents

Publication Publication Date Title
WO2011060945A3 (fr) Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires
WO2011060944A3 (fr) Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés
WO2012013331A3 (fr) Capsules d'ingrédients pharmaceutiques actifs et d'acides gras polyinsaturés pour le traitement de maladies de la prostate
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
EP4338805A3 (fr) Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
WO2011128635A3 (fr) Compositions pharmaceutiques anti-abus
ZA201202263B (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ734905A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2009091538A8 (fr) Composition pharmaceutique et méthode permettant de traiter l'hypertriglycéridemie et l'hypercholestérolémie chez des mammifères
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
IL210233A (en) Formulation of omega-3 fatty acid containing epa and dha and no other active ingredients other than omega-3 fatty acids
HK1198515A1 (en) Fatty acid compositions
GB2459809A (en) Fatty acid formulations and methods of use thereof
EP2506848A4 (fr) Substances permettant d'atténuer la survenue d'événements cardiaques majeurs qui contiennent un extrait de levure de riz rouge et des acides gras insaturés oméga 3 ou leur dérivé
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
MX2016004487A (es) Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
HUE050830T2 (hu) Sztatinok és omega-3 zsírsavak gyógyászati kiszerelése kapszulázáshoz
WO2011097276A8 (fr) Procédés et compositions pour traiter l'arthrite par de l'acide docosahexaénoïque
WO2011101866A3 (fr) Méthode de traitement d'une affection sensible à une thérapie par baclofène
WO2007090408A3 (fr) Comprimés enrobés, leurs procédés de préparation, et utilisations associées
GEP20125464B (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
WO2013136183A3 (fr) Forme d'administration d'une composition à base d'acides gras oxydables
PH12017500269A1 (en) Composite formulation for oral administration comprising omega-3 fatty acid esters and statins
WO2008115069A3 (fr) Composés chimiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080052613.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10781842

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012539231

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010321248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 219874

Country of ref document: IL

Ref document number: MX/A/2012/005744

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2781434

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4963/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010321248

Country of ref document: AU

Date of ref document: 20101119

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010781842

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127015768

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012122886

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012011902

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012011902

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120518